ON THE HORIZON – INDIVIDUALIZED BIOMARKER DRIVEN THERAPY IN CASTRATE RESISTANT PROSTATE CANCER (CRPC) –
July 28, 2016, at 7 pm.
Speaker: Dr. Shahrooz Eshaghian
Subject: Chemotherapy for Prostate Cancer: Earlier Better? Facts & Myths of a Systemic Approach in the Treatment of High Risk or Metastatic Prostate Cancer.
Speaker: Dr. Bob Leibowitz
Subject: Dr. Bob’s High Dose Testosterone Replacement Therapy Protocol for Successfully
Dr. Eshaghian will update us on what is fact and what is fiction when treating high risk and/or metastatic PCa. Dr. Bob will update us on ‘Challenging Prostate Cancer Treatment Biases; Is Nothing Sacred?”
Dr. Shahrooz Eshaghian is a Diplomate of the American Board of Internal Medicine with subspecialty in Hematology & Oncology. After graduating from UCLA, he received his doctorate of medicine from Albert Einstein College of Medicine. He completed his internship & residency at Cedars Sinai Medical Center and his fellowship at UCLA. He is an active attending physician at Cedars Sinai Medical Center and clinical instructor at UCLA. He strives to provide state-of-the-art, personalized and compassionate care to patients around the world and in the community at Compassionate Oncology Medical Group—internationally recognized for the treatment of prostate cancer—along with Dr. Robert Leibowitz.
Watch Dr. Bob & Dr. Eshaghian’s latest lecture, titled “Our Three-Pronged Approach Protocol for treatment of high-risk metastatic and/or recurrent prostate cancer and results from hundreds of PC patients utilizing High-Dose Testosterone Replacement Therapy”. Watch online by clicking here!